Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment,” in the Journal of Neurodevelopmental Disorders. The review of evidence suggests a central role for the endocannabinoid system (ECS) in neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS), and the potential role of CBD as a treatment for FXS.

“This publication describes the potential of Zygel as a treatment for fragile X syndrome based on the central role the endocannabinoid system plays in neuronal …

Full story available on Benzinga.com